Confirmed diagnosis of adenocarcinoma of the prostate

Participants with metastatic hormone refractory prostate cancer

Participants that have had at least one, but not more than two prior cytotoxic treatments for prostate cancer

Evidence of disease progression by at least one of the following:

1. two or more lesions on bone scan

2. progressive measurable disease

3. two documented increases in prostate-specific antigen (PSA)

Willing to use contraception throughout the study and for 12 weeks after study completion

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer